Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reddit Brigade! PRED is undervalued. I invested for the long term. fascinating Captain.
I agree with you, Brian
I agree with you, Brian
Yes, I am celebrating the 4th by buying more shares!
Not peer reviewed. 45 subjects doesn't "prove" the results. 45,000 maybe
TBT I have broken even on my shares. No way I am selling.
A recent study published in Nature Medicine found coronavirus antibodies may last only two to three months after a person becomes infected with Covid-19. Researchers examined 37 asymptomatic people, those who never developed symptoms, in the Wanzhou District of China. They compared their antibody response to that of 37 people with symptoms
https://www.cnbc.com/2020/07/01/pfizer-stock-jumps-after-it-reports-positive-data-in-early-stage-coronavirus-vaccine-trial.html
There is no evidence that once you have antibodies, you are "protected". Look to the Flu.
Yes, indeed.
Right on! Me too! I never invest in a stock I can't afford to lose.. my long term is at least 5 years
https://khn.org/news/abbott-rapid-test-problems-grow-fda-standards-on-covid-tests-under-fire/
Perspective: HIV infected blood transfusions in the early 80's. THAT was an "adverse reaction".
Yes. Long and strong based on my own DD
I have never invested on the Pink Sheets. I did with this stock because I have experience in lab quality control. I reviewed all scientific data. I also have experience in the financial markets, having worked at the largest, private mutual company. I am confident in my investment in the long term
Line 302
Name List of Medical Devices and Supplies Companies with Certification/Authorization from other Countries
http://en.cccmhpie.org.cn/Web/Content.aspx?queryStr=w7x08q7x15x15o3w8w1vS9z8w7x1X10x16x0X10x16o3w8w1u9v1u9vV5v1
Control F will aid you in a search.....
https://cen.acs.org/analytical-chemistry/diagnostics/COVID-19-antibody-tests-are-raising-as-many-questions-as-they-answer/98/i22
Good article written in laymen's terms. Did not cover POC rapid tests. I took Quest's test today.... results "as soon as possible, but not more than 30 days" LOL
Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis
https://www.medrxiv.org/content/10.1101/2020.04.22.20074914v1
Findings
In total, we identified 38 eligible studies that include data from 7,848 individuals. The analyses
showed that tests using the S antigen are more sensitive than N antigen-based tests. IgG tests
perform better compared to IgM ones, and show better sensitivity when the samples were taken
longer after the onset of symptoms. Moreover, irrespective of the method, a combined IgG/IgM
test seems to be a better choice in terms of sensitivity than measuring either antibody type
alone. All methods yielded high specificity with some of them (ELISA and LFIA) reaching
levels around 99%. ELISA- and CLIA-based methods performed better in terms of sensitivity
(90-94%) followed by LFIA and FIA with sensitivities ranging from 80% to 86%.
Interpretation
ELISA tests could be a safer choice at this stage of the pandemic. POC tests (LFIA), that are
more attractive for large seroprevalence studies show high specificity but lower sensitivity and
this should be taken into account when designing and performing seroprevalence studies.
Meta-analysis for stem cell transplantation for SPI:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322141/
Although some studies demonstrated no advantages with stem cell transplantation in the treatment of SCI30, most of the studies included in this meta-analysis indicated that MSC transplantations could significantly improve the sensory functions, including light touch and pinprick. Their results showed that sensory functions were improved in two respects. On the one hand, the improvement was reflected on the downward level of damaged spinal cord with loss of sensation. On the other hand, the sensory functions were improved from insensitivity or weak sensation to strong sensation.
I am researching meta-analysis research on antibody tests
I go by years too LTZ. I'm PREDicting, we will see a buy-out by one of the big guys in the future...
Note is says when, not if
Q codes are established to identify drugs, biologicals, and medical equipment or
services not identified by national HCPCS Level II codes, but for which codes are
needed for Medicare claims processing.
CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.
Way to go Brian903!
Just bought more shares on that DD!
Agreed. I fully support PRED's strategy with public disclosure. All ducks lining up. This stuff takes time!
The Wharton Jelly product has been sent back to FDA for further review for injection:
Request# 20.050
Topic/Issue:
Request to establish a new Level II HCPCS code to identify Wharton’s jelly-derived human cell
and tissue product.
Trade name: PolyCyte
Applicant’s suggested language: Q4XXX PolyCyte, per 0.5 mL
Applicant’s Summary
Predictive Biotech kindly requests to establish a new Level II HCPCS code to identify a
Wharton's jelly derived human cell and tissue product PolyCyte.
PolyCyte is a minimally manipulated human tissue allograft derived from the Wharton's jelly of
the umbilical cord. It is processed to preserve the cytokines, growth factors and proteins of
Wharton's jelly for homologous use. PolyCyte is intended for use in repair, reconstruction,
replacement or supplementation of a recipient's cells or tissue by performing the same basic
functions of Wharton's jelly in the recipient as it would in the donor. The amount and
administration (injected or topical) of the allograft is determined by the clinician based on the
intended use in each patient.
CMS Decision
Establish new level II HCPCS code Q4241 "Polycyte, for topical use only, per 0.5 cc."
Effective: 07/01/2020
After review of FDA’s guidance, it does not appear to CMS that the non-topical uses such as
injection for cartilage repair that are also the subject of this application are appropriate for
regulation solely under section 361 of the Public Health Service Act. CMS refers the applicant to
the FDA’s Tissue Reference Group or the Office of Combination Products to obtain written
feedback regarding how the product is appropriately regulated. After obtaining this written
feedback, the applicant is welcome to submit a complete HCPCS code application in a
subsequent coding cycle. Information for submitting questions to the TRG is located at:
https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/tissue-reference-group.
I believe it is a very big deal. CMS also approved an injection, but I am sure the procedures are highly restrictive.
Predictive Biotech kindly requests to establish a new Level II HCPCS code to identify an
amniotic matrix derived human cell and tissue product AmnioCyte Plus.
The amount and administration (injected or topical) of
the allograft is determined by the clinician based on the intended use in each patient
CMS Decision
Establish a new Level II HCPCS code Q4242 "Amniocyte plus, per 0.5 cc."
Effective: 07/01/2020
I believe the topical uses have been given FDA approval via the TRIP program, or CMS would not approve the addition of the billing codes. Assumption at this point.
Added billing codes for insurance. Outstanding!
Great DD Brian! Adding codes for insurance billing, approved by CMS!
I signed and shared. Thanks for the post!
Huh? We longs are buying shares. I will gladly buy yours at $5 pps
The lab validated the tests before they submitted for the EUA.